Evidence map›Paper›PMID 27914852›Full record

ReviewThe Lancet. Infectious diseases2017

A call to strengthen the global strategy against schistosomiasis and soil-transmitted helminthiasis: the time is now.

Nathan C Lo, David G Addiss, Peter J Hotez, Charles H King, J Russell Stothard, Darin S Evans, Daniel G Colley, William Lin, Jean T Coulibaly, Amaya L Bustinduy and 8 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 7 pooled it
19.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 7 syntheses or guidelines pooled it, 175 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Effectiveness of Four Different Interventions Against Schistosoma haematobium in a Seasonal Transmission Setting of Côte d'Ivoire: A Cluster Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 5 countries.

Nathan C LoDivision of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA; Division of Epidemiology, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: nathan.lo@stanford.edu.
David G AddissChildren Without Worms, Task Force for Global Health, Decatur, GA, USA.
Peter J HotezSabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine at Baylor College of Medicine, Houston, TX, USA; Department of Biology, Baylor University, Waco, TX, USA; James A Baker III Institute for Public Policy, Rice University, Houston, TX, USA.
Charles H KingCenter for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, USA.
J Russell StothardDepartment of Parasitology, Liverpool School of Tropical Medicine, Liverpool, UK.
Darin S EvansUnited States Agency for International Development, Global Health, Washington, DC, USA.
Daniel G ColleyCenter for Tropical and Emerging Global Diseases and the Department of Microbiology, University of Georgia, Athens, GA, USA.
William LinGlobal Public Health, Johnson & Johnson, New Brunswick, NJ, USA.
Jean T CoulibalyUnité de Formation et de Recherche Biosciences, Université Félix Houphouët-Boigny, Abidjan, Côte d'Ivoire; Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire; Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.
Amaya L BustinduyClinical Research Department, London School of Hygiene & Tropical Medicine, London, UK.
Giovanna RasoSwiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.
Eran BendavidDivision of General Medical Disciplines, Stanford University, Stanford, CA, USA; Center for Health Policy and the Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA.
Isaac I BogochDepartment of Medicine, University of Toronto, Toronto, ON, Canada; Division of Internal Medicine and Infectious Diseases, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Alan FenwickSchistosomiasis Control Initiative, Imperial College London, London, UK.
Lorenzo SavioliGlobal Schistosomiasis Alliance, Chavannes de Bogis, Switzerland.
David MolyneuxDepartment of Parasitology, Liverpool School of Tropical Medicine, Liverpool, UK.
Jürg UtzingerSwiss Tropical and Public Health Institute, Basel, Switzerland; University of Basel, Basel, Switzerland.
Jason R AndrewsDivision of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Stanford University · USLiverpool School of Tropical Medicine · GBSwiss Tropical and Public Health Institute · CHCenter for Global Health · USImperial College London · GBJohnson & Johnson (United States) · USLondon School of Hygiene & Tropical Medicine · GBSabin Vaccine Institute · USThe Task Force for Global Health · USUnited States Agency for International Development · USUniversité Félix Houphouët-Boigny · CIUniversity of Georgia · USUniversity of Toronto · CA

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007365 · NIGMS · STANFORD UNIVERSITY · PI CHUA, KATRIN F · 1985 to 2021
$33.8M
NIGMS NIH HHS T32 GM007365
6 · The paper itself

Abstract

In 2001, the World Health Assembly (WHA) passed the landmark WHA 54.19 resolution for global scale-up of mass administration of anthelmintic drugs for morbidity control of schistosomiasis and soil-transmitted helminthiasis, which affect more than 1·5 billion of the world's poorest people. Since then, more than a decade of research and experience has yielded crucial knowledge on the control and elimination of these helminthiases. However, the global strategy has remained largely unchanged since the original 2001 WHA resolution and associated WHO guidelines on preventive chemotherapy. In this Personal View, we highlight recent advances that, taken together, support a call to revise the global strategy and guidelines for preventive chemotherapy and complementary interventions against schistosomiasis and soil-transmitted helminthiasis. These advances include the development of guidance that is specific to goals of morbidity control and elimination of transmission. We quantify the result of forgoing this opportunity by computing the yearly disease burden, mortality, and lost economic productivity associated with maintaining the status quo. Without change, we estimate that the population of sub-Saharan Africa will probably lose 2·3 million disability-adjusted life-years and US$3·5 billion of economic productivity every year, which is comparable to recent acute epidemics, including the 2014 Ebola and 2015 Zika epidemics. We propose that the time is now to strengthen the global strategy to address the substantial disease burden of schistosomiasis and soil-transmitted helminthiasis.

Indexed as

Guidelines as TopicAfrica South of the SaharaAnthelminticsGlobal HealthHelminthiasisHumansMorbidityQuality-Adjusted Life YearsSchistosomiasisSoilAnthelminticsSoil

Identifiers

PMID27914852
PMCPMC5280090
OpenAlexW2558861418

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.